News

Month Year

Month Year

Jul 2, 2021

Sanofi Canada continues to invest in modern diabetes research to improve outcomes for people living with diabetes
Jun 28, 2021

New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin
Jun 17, 2021

DUPIXENT® (dupilumab injection) pre-filled pen now available in Canada, providing convenient self-administration option for people with type 2 inflammatory diseases
Jun 10, 2021

Sanofi Canada awards first annual Biogenius Grants, strengthening equity in STEM learning for Canadian students
Jun 1, 2021

Quebec extends public reimbursement of DUPIXENT® (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis to include adolescents
May 25, 2021

DUPIXENT® (dupilumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate-to-severe atopic dermatitis
Mar 31, 2021

Sanofi to build new manufacturing facility in Toronto to strengthen domestic pandemic preparedness and increase global supply of high-dose influenza vaccine
Mar 22, 2021

Sanofi Canada earns Gold-level gender parity certification for the second straight year
Feb 23, 2021

Health Canada approves DUPIXENT® (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years
Jan 28, 2021

Sanofi Canada launches Biogenius Grant for high schools, strengthening commitment to equity in the field of STEM learning

Show per page